Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/52—Cytokines; Lymphokines; Interferons
  • C07K14/555—Interferons [IFN]

Definitions

• This invention relates to improvements in or relating to a process for producing the substances called interferons, which have non-specific antiviral effects.
• An interferon is an antiviral proteinaceous substance which is produced by a cell in response to stimulation by a virus or other inducing agent.
• Inferferons can be produced by most cells, for example white blood cells, fibroblasts, lymphoblastoid cells, cells of epithelial types such as kidney cells or HeLa cells, myeloma cells, etc.
• the particular cells chosen to produce interferon will depend on the product required, since interferons have characteristics depending on the host from which they are derived. If interferon is required for use in man, human cells are the preferred source. When formed, an interferon is excreted from the cell, and can then interact with other cells to inhibit virus replication or produce other effects. This antiviral effect is not specific to particular viruses, though some viruses are more sensitive to the effect of interferons than others.
• Interferon has also been used in a chemotherapeutic regime for treatment of certain types of cancers, and appears to have a beneficial effect (Strarider. H., Cantell, K., et al., Fogargty Intern. Center Proc., U.S. Govt. Printing Office, Washington D.C., 28: pp 377-381, 1977 Presented at the Conference at the National Institute of Health, Bethezda, Dec. 9-11, 1974.
• human peripheral blood leukocytes human fibroblasts and human lymphoblastoid cells.
• human peripheral leukocytes production of interferon from human peripheral leukocytes is limited by the availability of human blood.
• Large scale production of interferon from fibroblasts is hampered by the fact that these cells will only grow when adherent to a surface.
• Lymphoblastoid cells have the advantage that they can be grown in large suspension cultures, and can be induced to form interferon by treatment with a virus.
• interferon produced from human lymphoblastoid cells by such methods can vary considerably, for example titres as high as 60-80 mega units (a mega unit equals 10 S units of interferon in terms of the Medical Research Council research standard preparation of interferon, 69/19, see N. Finter, Interferons, 1973, pp. 485-4.86, published by North Holland) of interferon per litre may be obtained, corresponding to yields of 30-40 mega units per 10" cells; on other occasions the titres may be only 1 mega unit or less per litre (or 0.5-0.7 mega units per 10 9 cells) from similar cells induced under apparently identical conditions. The causes of such variations in the yield of interferon are unknown.
• interferon levels may be increased slightly by changing the medium in which the cells are suspended at the time of induction of interferon production.
• a process for producing interferon which comprises adding an interferon inducer to cells which are susceptible to being induced to form interferon characterized in that prior to induction the cells are incubated in a medium containing an amount of a straight chain alkanoic acid, or a salt thereof, effective to enhance interferon production without being toxic to the cells.
• the cells selected for interferon production are chosen according to the requirement, thus if the interferon is for administration to humans, then human cells are the type usually selected.
• the cells used may be epithelial cells, or lymphoblastoid cells such as Namalva cells or other lymphoblastoid cell lines. Lines of lymphoblastoid cells that can be serially propogated in culture are readily derived from cultures of peripheral human blood leukocytes by well established methods (see for example, Hope, J. H., Home, M. K., Scott, W., lnt. J. Cancer, 3, pp 857-866 (1978), Hope, J. H., Horne, M. K. , Scott, W., Int. J.
• the leukocytes may be obtained from normal or diseased individuals, and they may be derived "spontaneously" if the cells are already infected with Epstein-Barr Virus (EBV), or they may be derived from cultures of leukocytes that are not infected with EBV, e.g. umbilical cord blood leukocytes, to which EBV of infectious mononucleosis or Burkitt lymphoma origins have been added.
• EBV Epstein-Barr Virus
• Lymphoblastoid cell lines are readily derived from the cells of patients with Burkitt's lymphoma as these are already infected with EBV.
• One particular line of Namalva was derived in Sweden by Prof. G. Klein (Nyornoi, 0., Klein G., Adams, A., Dombon, L., Int. J. Cancer, 12, pp 396-408 (1973)) from cells obtained from an African female child of that name. Cells of this line have been found to produce large amounts of interferon when suitably stimulated (Strander, H., Morgensen, K. E., Cantell, K., J. Clin. Micro., 1, pp 116-117, (1975)). The subculture of this cell line was obtained from Dr.
• Ion Gresser (Villejuif, France) in January 1975. At that time the line was adapted to grow on medium RMPI 1640 with 10% foetal calf serum. In these laboratories the cells have been adapted to grow on the same medium supplemented with 5-7% serum derived from 6-8 month old calves and they have been subcultured two or three times a week during an 18 month period. A stock of these cells now termed Namalva/WRL has been laid down in a number of ampoules which are stored in liquid nitogen. These cells have been shown to be free from mycoplasma infections and samples have been deposited with the American Type Culture Collection. *
• Namalva/WRL cells were used in the examples described hereinafter but the invention also has been applied to other sub-lines of Namalva cells and other lymphoblastoid cells.
• the straight chain alkanoic acid used in the medium preferably has from 2 to 8 carbon atoms, more preferably 3 to 6 carbon atoms, and most preferably it is butyric acid. If the acid itself is used, then on addition to the medium, which will contain various inorganic or organic salts, the salt of the acid is usually formed. Alternatively, it is possible to add the salt of the carboxylic acid to the medium in which case such salts as the sodium, potassium or ammonium salt may be used.
• human lymphoblastoid cells such as the Namalva cell line
• a growth medium such as RPMI 1640 (Moore, G. E., et. al., 1967, J. Amer. Med. Assoc. 199, 519-524) supplemented with serum, for example calf or horse serum, usually at 5%-10% (v/v).
• the cells are grown in suspension until they have reached an adequate concentration, for example from 0.5 to 10 x 10 s cells/ml after which they can be conveniently processed for interferon production.
• the cell concentration is adjusted to between 0.25 to 6 x 10 B cells/ml, preferably 0.5 to 3 x 10 8 cells/ml, most preferably 1 x 10 6 cells/ml in a medium which can be one of the following: (a) fresh growth medium, (b) the spent growth medium in which the cells were previously grown, supplemented with fresh growth medium, or (c) the spent medium supplemented with fresh nutrients.
• the carboxylic acid or salt thereof may be added to the cell culture to give a final concentration of 0.1 to 10mM, preferably 0.2 to 5mM, most preferably 0.5 to 2.0mM.
• concentration is limited by the toxicity of the carboxylic acid for the cells but should be present in an amount so as to be effective in the enhancement of interferon production, and so the optimum balance between improved interferon yield and cell toxicity must be determined for the acid selected for use.
• carboxylic acids other than butyric acid different molarities may be preferable.
• the cells After incubation the cells are then separated from the medium containing the carboxylic acid by some suitable method which does not damage them, for example centrifugation or filtration.
• the cells may according to the known art (Tovey M. G., et. al. Proc. of Soc. for Exp. Biol. et Med., 146, 809-815 (1974)) then be resuspended in a suitable medium, and induced to form interferon.
• they may be resuspended in medium RPM1 1640, containing no serum or supplemented with up to 5% v/v serum, to give a final cell concentration of from 0.25 to 8 x 10 8 cells/ml, preferably 0.5 to 4 x 10 6 cells/ml.
• a suitable inducer such as a virus, for example Sendai virus, is added to the cell suspension to give a final concentration of 5 to 200 HAU/ml, preferably 20 to 50 HAU/ml.
• a virus for example Sendai virus
• the cell suspension is incubated for a period of 12 to 48 hours at a temperature of from 34 to 37°C.
• the cell culture can conveniently be incubated overnight, during which time interferon is liberated from the cells into the medium.
• the cells are removed by for example centrifugation, leaving a supernatant containing the crude interferon.
• the advantage of incubating the cells in the presence of a straight chain alkanoic acid or salt thereof, before inducing them to form interferon is that relatively high yields of interferon are produced, that is 5-50 mega units per litre or higher, more consistently than in the absence of the treatment.
• cells that have been adapted to grow in a medium containing a low serum supplement, e.g. 1 to 2% v/v will produce as much interferon as cells growing in medium supplemented with three to four times the amount of serum. This feature is of considerable importance since the cost of the serum comprises a large part of the cost of producing the interferon.
• a further advantage of incubating the cells in the presence of a carboxylic acid is that the step of priming the cells with a small amount of homologous interferon becomes redundant, resulting in a saving in production costs.
• Human lymphoblastoid cells of the Namalva/WRL line were grown in suspension in a mechanically stirred 100 litre vessel in a growth medium consisting of medium RMPI 1640 supplemented with 7% calf serum, neomycin and polymyxin, and with bicarbonate for pH control.
• medium RMPI 1640 supplemented with 7% calf serum, neomycin and polymyxin, and with bicarbonate for pH control.
• 10 litres were withdrawn from the vessel and diluted with an equivalent volume of fresh growth medium.
• Butyric acid was added to give a final concentration of 1 mM, and the cells were incubated at 37°C for 48 hours. During this period, the cells were stirred in glass flasks, and the ratio between the volume of cell suspension and the overlying air was approximately 2:5.
• the cells were centrifuged at 2,500 r.p.m. for 5 minutes at 20°C in a MSE Coolspin centrifuge.
• the cell pellet was resuspended in medium RMPI 1640 containing 2% calf serum, and the cell concentration was estimated.
• the cells were diluted to a final concentration of 2.75 x 10 S cells per ml, and to prime them, pre-formed lymphoblastoid interferon was added to give a final concentration of approximately 100 reference interferon units per ml.
• Sendai virus was then added to a final concentration of 75 haemagglutination units per mi. to induce the interferon formation.
• the cell suspension was put into Thompson bottles (300 ml per bottle), which were incubated at 35°C overnight. On the following day, the cell suspensions were centrifuged at 3,000 r.p.m. for 10 minutes at 4°C in a Coolspin centrifuge. The supernatant fluid, containing the crude interferon, was acidified for 24 hours at pH 2, and then neutralised to pH 4 for subsequent storage.
• Namalva/WRL cells were grown to a concentration of 2.5 x 10 * cells/ml in the medium used in Example 1 and were collected by centifugation at 800 x g for 10 minutes; the cell pellet was resuspended in fresh growth medium.
• the cell suspension was diluted to a final concentration of 1.3 x 10 * cells/ml, and 50 ml samples were dispensed into 75 cm 2 plastic tissue culture flasks. Different amounts of a 100mM solution of sodium butyrate in phosphate buffered saline were then added to individual flasks to give a final concentration of sodium butyrate of 0, 0.1, 0.2, 0.5, 1,2 and 5 mM.
• the flasks were incubated at 36°C for 48 hours, and then the cells in each flask were: concentrated by centrifugation at 800 x g for 5 minutes. Each cell pellet was resuspended to a final, concentration of 4.3 x 10 * cells/ml in RMPI 1640 medium containing 2% (v/v) calf serum (maintenance medium). Samples of 10 ml of each cell suspension were placed in two 25 cm 2 plastic tissue culture flasks, which were induced to form interferon by the addition of Sendai virus to give a final concentration of 40 HAU/ml.
• the flasks were returned to 36°C for 20 hours.
• the interferon produced by each culture was harvested by sedimenting the cells at 1,000 x g for 5 minutes.
• the supernatant containing the interferon was adjusted to pH 2.0 by the addition of concentrated hydrochloric acid and stored at 4°C overnight. On the following day, the pH was adjusted to 7.0, and each sample was assayed for its interferon content.
• Example 2 The method of preparing interferon as described in Example 2 was followed except that the sodium butyrate was replaced by sodium acetate, and the concentrations used were 0, 0.2, 1.0, 5.0 mM. The results were as follows
• the cells in the flask which received no sodium butyrate and in one of the flasks which received 1 mM sodium butyrate were sedimented from the medium at 1000 x g for 5 minutes, resuspended in RPMI 1640 medium containing 2% v/v calf serum and adjusted to 3.0 x 10 6 cells/ml. They were induced to synthesize interferon by addition of Sendai virus to a final concentration of 20 HAU/ml.
• the cells in the remaining flasks were pooled, centrifuged at 1000 x g for 5 minutes and resuspended to a concentration of 1.0 x 10 8 cells/ml in fresh RPMI 1640 growth medium containing no sodium butyrate.
• Plastic tissue culture flasks having a surface area of 25 cm 2 available for cell growth were seeded with V3 cells, Christofinis G. J., J. Med. Micro, 3(2), 251 ⁇ 258, 1970, at 1.5 x 10 5 cells/ml in 10 ml of Eagles Basal medium containing 4% v/v of foetal calf serum.
• the flasks were placed at 36°C for 24 hours to allow the cells to attach to the plastic and establish.
• the growth medium was removed from each flask and the cells re-fed with 10 ml of fresh growth medium.
• sodium butyrate in phosphate buffered saline was added to a final concentration of 2mM.
• Namalva/WRL cells were sedimented from spent growth medium and resuspended in fresh RPMI 1640 medium containing 7% v/v calf serum to a concentration of 1.38 x 10 8 cells/ml. 500 ml were placed in each of two 1 litre glass jars, and to one culture sodium butyrate in phosphate buffered saline was added to a final concentration of 1 mM. The cultures were stirred at 36° for 48 hours. The cells were recovered by centrifugation and resuspended in RPMI 1640 medium containing 2% v/v calf serum to a concentration of 5.0 x 10 6 cells/ml. Aliquots of 10 ml of these cell preparations were induced with the agents tested. The supernatants from the virus-induced cultures were processed as usual at pH 2 before being assayed for their interferon content. The results were as follows:-
• Polyribosinic acid - polyribocytidylic acid complex was obtained from P-L Biochemicals Inc. Lot No. 447121.
• Namalva/WRL cells which normally grow in medium RPMI 1640 containing 7% calf serum, were adapted to grow in medium containing only 2% calf serum. These cultures regularly yielded cell counts of 1.5-2.0 x 10 6 /ml.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Zoology (AREA)
• Genetics & Genomics (AREA)
• Medicinal Chemistry (AREA)
• Gastroenterology & Hepatology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Toxicology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Peptides Or Proteins (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=10298554

Family Applications (1)

Country Status (15)

Cited By (1)

Families Citing this family (22)

Family Cites Families (2)

• 1978
  • 1978-07-11 CS CS784645A patent/CS215108B2/cs unknown
  • 1978-07-14 IT IT50322/78A patent/IT1107573B/it active Protection Beyond IP Right Term
  • 1978-07-14 AU AU38049/78A patent/AU524099B2/en not_active Expired
  • 1978-07-14 PL PL1978208407A patent/PL110704B1/pl unknown
  • 1978-07-14 AT AT510378A patent/AT362334B/de not_active IP Right Cessation
  • 1978-07-14 HU HU78WE579A patent/HU179655B/hu not_active IP Right Cessation
  • 1978-07-14 JP JP8599878A patent/JPS5420119A/ja active Granted
  • 1978-07-14 EP EP78100395A patent/EP0000520B1/en not_active Expired
  • 1978-07-14 DE DE7878100395T patent/DE2860559D1/de not_active Expired
  • 1978-07-14 CA CA307,456A patent/CA1115209A/en not_active Expired
  • 1978-07-14 US US05/924,703 patent/US4216203A/en not_active Expired - Lifetime
  • 1978-07-14 IL IL55143A patent/IL55143A0/xx not_active IP Right Cessation
  • 1978-07-14 DK DK316978A patent/DK147625C/da not_active IP Right Cessation
  • 1978-07-14 ES ES471721A patent/ES471721A1/es not_active Expired
  • 1978-07-14 FI FI782249A patent/FI60971C/fi not_active IP Right Cessation

Also Published As

Similar Documents

Legal Events